The U.S. Food and Drug Administration (FDA) updated the label for Orgovyx (relugolix) on October 10, 2025. This revision specifically addresses the indication and usage of the drug, confirming its role in the treatment of adult patients with advanced prostate cancer.
Background
Orgovyx (relugolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist. The updated label confirms that Orgovyx is indicated for the treatment of adult patients with advanced prostate cancer.
What this means
This label revision provides clear and specific guidance for healthcare professionals regarding the appropriate use of Orgovyx. By explicitly stating that Orgovyx is indicated for the treatment of adult patients with advanced prostate cancer, the FDA ensures that clinicians have precise information for prescribing decisions. This clarity helps to align clinical practice with the approved therapeutic scope of the drug, benefiting patient care by ensuring treatments are administered according to the most current regulatory standards. For researchers and patient advocates, this updated language offers a definitive understanding of the drug's approved application, which is crucial for informing future studies, policy discussions, and patient education initiatives. The precise wording on the label is vital for all stakeholders in the healthcare ecosystem.
Source
The information regarding this label revision was sourced from the U.S. Food and Drug Administration (FDA). The updated indication and usage details for Orgovyx became effective on October 10, 2025, and are available on the dailymed.nlm.nih.gov website, which hosts official drug labeling information.